AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients

  • AstraZeneca plc's AZN Tagrisso (osimertinib) cuts the risk of death by 51% in patients with a certain form of lung cancer diagnosed early enough to remove their tumor surgically, trial data showed.
  • Data from the ADAURA Phase 3 trial showed Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.
  • In 2022, Tagrisso was the leading revenue-generating drug for the company, raking in $5.4 billion.
  • Related: AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer.
  • Tagrisso reduced the risk of death by 51% compared to the placebo in both the primary analysis population and the overall trial population.
  • In the primary analysis population, an estimated 85% of patients treated with Tagrisso were alive at five years compared to 73% on placebo. 
  • In the overall trial population, 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo. 
  • Median OS was not yet reached in either population or treatment group. 
  • Adverse events at Grade 3 or higher from all causes occurred in 23% of patients in the Tagrisso arm versus 14% in the placebo arm.
  • Price Action: AZN shares are up 0.73% at $73.12 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!